tbuckley/cabot-search huggingface dataset:
Oral Busulfan and Cyclophosphamide or IV Busulfan and Fludarabine for Allogeneic HSCT in Hematologic Malignancies?.
Authors: J. Altman, N. Venepalli, J. Monreal, K. Rashid, L. Gordon, J. Winter, S. Williams, M. Tallman, O. Frankfurt, A. Evens, S. Singhal, J. Mehta
Journal: Blood (2006)
Sports injuries and illnesses in the Lillehammer 2016 Youth Olympic Winter Games
Authors: Kathrin Steffen, Christine Holm Moseid, Lars Engebretsen, Pia K Søberg, Olav Amundsen, Kristian Holm, Thomas Moger, Torbjørn Soligard
Journal: British Journal of Sports Medicine (2016)

Injury and illness surveillance during high-level youth sports events is an important first step in health prevention and caretaking of the young elite athletes.To analyse injuries and illnesses that occurred during the 10 days 2nd Youth Olympic Winter Games (YOG), held in Lillehammer 2016.We recorded the daily occurrence (or non-occurrence) of injuries and illnesses through the reporting of (1) all National Olympic Committee (NOC) medical teams and (2) the polyclinic and medical venues by the Lillehammer Organising Committee (LYOCOG) medical staff.In total, 1083 athletes (48 double-starters), 46% (n=502) of them females, from 70 NOCs were registered in the study. NOCs and LYOCOG reported 108 injuries and 81 illnesses, equalling to 9.5 injuries and 7.2 illnesses per 100 athletes. The percentage of injured athletes was highest in the snowboard and ski slopestyle and cross disciplines, alpine skiing and skeleton, and lowest in the Nordic skiing disciplines. Approximately, two-thirds of the injuries (n=71, 65.7%) prevented the athlete from training or competition, while 10 injuries (9.3%) were registered with an estimated absence from sport for >7 days. The rate of illness was highest in curling and the Nordic skiing disciplines with most of them being respiratory tract infections (81.5%).Overall, 9% of the athletes incurred at least one injury during the games, and 7% an illness, which is similar to the first YOG in Innsbruck 2012 and slightly lower compared with previous Winter Olympic Games. The incidence of injuries and illnesses varied substantially between sports.
PTU-046 The Use of Entonox as an Analgesic During Colonoscopy – Ninewells Endoscopy Unit Experience
Authors: W Dowdles
Journal: Gut (2016)

<h3>Introduction</h3> Entonox is a safe and effective method of analgesia used for patients undergoing colonoscopy. It has a number of advantages over sedo-analgesia and is available for use in a large number of Endoscopy Units in the UK. The aim of the study was to assess the effectiveness of Entonox as an analgesic during colonoscopy in our unit, and to evaluate the experience of patients, nurses and endoscopists involved. <h3>Methods</h3> This study was carried out over a two month period between 1<sup>st</sup> June 2014 and 31<sup>st</sup> July 2014. All patients undergoing out-patient colonoscopy and all trained endoscopy nurses and endoscopists who worked in the unit were invited to take part. A questionnaire, focussing on discomfort, anxiety and discharge planning was completed by patients choosing to have Entonox before leaving the department. Nurses and endoscopists were questioned on their experience of Entonox as an analgesic and the effect on flow within the unit, at the end of the study period. <h3>Results</h3> 489 patients had a colonoscopy during the study period, 89 (18%) chose to have Entonox. Of these patients 56% were male. 71% were aged between 40 and 69 years. 89% of procedures were diagnostic and 11% therapeutic. Colonoscopy was complete to caecum in 99% of procedures. 15% of patients experienced mild side effects such as dry mouth, light headedness and sweating. 84% of patients who used Entonox were fit for discharge less than 30 minutes after the procedure: 23% drove home and 89% went home without an escort. Patients reported a mean satisfaction score of 8.4 and 70% said they would use Entonox again. Of the 21 endoscopy nurses and 17 endoscopists who completed the end of study questionnaire, 95% of nurses and 94% of endoscopists were satisfied with Entonox as an effective method of pain control for colonoscopy. All nurses felt Entonox should continue to be offered to patients and 88% of Endoscopists said it should be implemented in NHS Tayside’s other two endoscopy units. There was a cost saving of £75.05 over the two month study period: This would make a predicted annual saving of £772.35. <h3>Conclusion</h3> Our study has shown that Entonox is a suitable analgesic option for our patients having a colonoscopy. It is safe and simple to use, does not impact on colonoscopy completion rate and is cost effective. Patients have a shorter recovery period and are discharged quickly after the procedure. Patients are able to drive after the procedure and go home without an escort. Patients, nurses and endoscopists all reported high satisfaction scores. Entonox will continue to be offered to patients within Ninewells Hospital Endoscopy Unit and is currently being introduced in the other NHS Tayside Endoscopy Units. <h3>Disclosure of Interest</h3> None Declared
The Novel Anti-Myeloma Agent Chaetocin Enhances Tumor-Specific Dendritic Cell Response Via the Induction of Heat Shock Protein and Cancer Testis Antigens On Myeloma Cells
Authors: Thanh-Nhan Nguyen-Pham, Hyun Ju Lee, Huong Thi Thanh Tran, Manh-cuong Vo, My-Dung Hoang, Nuri Choi, Hyeoung-Joon Kim, Je-Jung Lee
Journal: Blood (2012)
Mature T Cells in the Graft Improve NK Cells Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation.
Authors: Stephanie Nguyen, Mathieu Kuentz, Jean-Paul Vernant, Nathalie Dhedin, Oualid Bouteraa, Patrice Debre, Vincent Vieillard
Journal: Blood (2006)
Biallelic mutations in IRF8 impair human NK cell maturation and function
Authors: Emily M. Mace, Venetia Bigley, Justin T. Gunesch, Ivan K. Chinn, Laura S. Angelo, Matthew A. Care, Sheetal Maisuria, Michael D. Keller, Sumihito Togi, Levi B. Watkin, David F. LaRosa, Shalini N. Jhangiani, Donna M. Muzny, Asbjørg Stray-Pedersen, Zeynep Coban Akdemir, Jansen B. Smith, Mayra Hernández-Sanabria, Duy T. Le, Graham D. Hogg, Tram N. Cao, Aharon G. Freud, Eva P. Szymanski, Sinisa Savic, Matthew Collin, Andrew J. Cant, Richard A. Gibbs, Steven M. Holland, Michael A. Caligiuri, Keiko Ozato, Silke Paust, Gina M. Doody, James R. Lupski, Jordan S. Orange
Journal: Journal of Clinical Investigation (2016)

Human NK cell deficiencies are rare yet result in severe and often fatal disease, particularly as a result of viral susceptibility. NK cells develop from hematopoietic stem cells, and few monogenic errors that specifically interrupt NK cell development have been reported. Here we have described biallelic mutations in IRF8, which encodes an interferon regulatory factor, as a cause of familial NK cell deficiency that results in fatal and severe viral disease. Compound heterozygous or homozygous mutations in IRF8 in 3 unrelated families resulted in a paucity of mature CD56dim NK cells and an increase in the frequency of the immature CD56bright NK cells, and this impairment in terminal maturation was also observed in Irf8–/–, but not Irf8+/–, mice. We then determined that impaired maturation was NK cell intrinsic, and gene expression analysis of human NK cell developmental subsets showed that multiple genes were dysregulated by IRF8 mutation. The phenotype was accompanied by deficient NK cell function and was stable over time. Together, these data indicate that human NK cells require IRF8 for development and functional maturation and that dysregulation of this function results in severe human disease, thereby emphasizing a critical role for NK cells in human antiviral defense.
Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.
Authors: Johanna Tischer, Susanne Fritsch, Dusan Prevalsek, Max Hubmann, Veit Bücklein, Anna K Zöllner, Christoph Schulz, Roland Reibke, Nicole Engel, Christina T Rieger, Christoph Schmid, Georg Ledderose, Wolfgang Hiddemann, Andreas Hausmann
Journal: Blood (2012)
FRI0198 Which Seronegative RA Patients Respond To Rituximab?: Table 1.
Authors: E.M. Vital, E.M. Hensor, P. Emery
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> RF-CCP- RA patients have inferior response to rituximab (RTX) but a subset respond as well as seropositive RA. RF-CCP- RA may have alternative markers of B cell dysfunction such as ANA or hypergammaglobulinaemia. <h3>Objectives</h3> To identify clinical predictors of response to rituximab in RF-CCP- RA as a means to select patients suitable for RTX. <h3>Methods</h3> Data from 7 clinical trials were pooled. Binary logistic regression models were used to test whether baseline factors affected odds of ACR20 at 24 weeks in patients negative for RF and CCP patients, controlling for trial. Non-response was imputed for patients who withdrew or were retreated prior to 24 weeks. Interaction terms were added to identify potential treatment effect modifiers (p&lt;0.2 criterion). <h3>Results</h3> 396 patients had data available (mean age 52.3, 82% female, mean baseline DAS28CRP 5.5) of whom 155 (39%) achieved ACR20 at 24 weeks. Odds ratios are presented in Table 1. In addition to expected markers of therapy response, we found a relationship between higher IgG and increased odds of response with an interaction with rituximab dose. Overall, 2x1000mg was more effective than placebo, and the level of IgG did not influence the odds of response. In contrast, 2x500mg was increasingly effective compared to placebo with increasing IgG titre. Data on ANA status were more limited. We tested a model including ANA in a set of 301 patients. There was a trend to greater response in ANA positive patients (OR 1.49, CI 0.87 – 2.58). Controlling for ANA the interaction with IgG remained for rituximab 500mg (OR 1.1, CI 0.96 – 1.34) <h3>Conclusions</h3> The lower dose RTX appeared less effective in this group of patients overall. A subset of RF-CCP- patients with alternative markers of B cell mediated inflammation have more scope to respond to RTX. However, this effect is less relevant when the licensed dose is used. The efficacy of RTX in RF-CCP-ANA+ arthritis patients supports its efficacy in connective tissue diseases. <h3>Acknowledgement</h3> This study was supported by a research grant from Roche. <h3>Disclosure of Interest</h3> None declared
Paroxysmal Nocturnal Hemoglobinuria (PNH) In Pediatric Patients: Review of a Single Center Series
Authors: Kevin J. Curran, Nancy A. Kernan, Susan E. Prockop, Andromachi Scaradavou, Trudy N. Small, Hugo Castro-Malaspina, David Araten, Donna DiMichele, Richard J. O'Reilly, Farid Boulad
Journal: Blood (2010)
Platelet-Localized FXI Promotes a Glycoprotein Ib Alpha Dependent Feedback Loop in Arterial Hypertension and Vascular Inflammation
Authors: Jeremy Lagrange, Sabine Kossmann, Jäckel Sven, Jurk Kerstin, Moritz Ehlken, Tanja Schönfelder, Maike Knorr, Moritz Brandt, Susanne Karbach, Andreas Daiber, Matthias Oelze, Christoph Reinhardt, Karl Lackner, Brett P. Monia, Ulrich Walter, Zaverio M. Ruggeri, Thomas Renné, Wolfram Ruf, Thomas Münzel, Philip Wenzel
Journal: Blood (2015)
AB0894 The Significance of Urinary Beta-2 Microglobulin Level for Differential Diagnosis of Familial Mediterranean Fever and Acute Appendicitis
Authors: Y. Ugan, H. Korkmaz, A. Doğru, Y.S. Koca, A. Balkarlı, F. Aylak, S.E. Tunc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The clinical and laboratory parameters widely used are not specific to discriminate the abdominal pain due to FMF attack from that of acute appendicitis. <h3>Objectives</h3> The present study aims to investigate the urinary beta-2 microglobulin (U-β<sub>2</sub>M) level as a potential parameter to identify these two diseases mimicking each other. <h3>Methods</h3> A total of 51 patients with established FMF diagnosis due to Tel Hashomer criteria on colchicine treatment (1–1.5mg/day), 15 patients with acute appendicitis who had appropriate clinical picture and were also supported pathologically after the surgery, and 20 healthy controls were enrolled in the study. Of the 51 patients with FMF, 25 were at an attack period, while remaining 26 were not. For the diagnosis of acute attack, as well as physical examination, laboratory tests including white blood cell count, C-reactive protein, and erythrocyte sedimentation rate were performed. From urine specimens urinary Beta-2 Microglobulin, microalbumin, and N-acetyl glucosaminidase (U-NAG) were measured. <h3>Results</h3> U-β<sub>2</sub>M levels were significantly higher in acute appendicitis group compared to FMF group during attack period, FMF group during attack free period, and control groups (p&lt;0.001, p&lt;0.001, and p&lt;0.001 respectively). U-NAG and microalbuminuria were significantly higher in acute appendicitis, FMF group during attack period, and FMF group during attack free period compared to controls (U-NAG p&lt;0.001, p=0.016, p=0.004, microalbuminuria p&lt;0.001, p&lt;0.001, p&lt;0.001 respectively). Microalbuminuria was significantly higher in acute appendicitis group compared to the FMF group during attack period (p=0.004). <h3>Conclusions</h3> Determination of U-β<sub>2</sub>M levels may be helpful for differential diagnosis of peritonitis attacks of FMF patients on colchicine treatment, and acute appendicitis. However, this finding should be substantiated with other studies. <h3>Disclosure of Interest</h3> None declared
Cap Analysis of Gene Expression (CAGE) Sequencing Reveals Alterations of the Transcript Signatures in Acute Monocytic Leukemia Cells By Fatty Acid Oxidation Inhibition
Authors: Yoko Tabe, Marina Konopleva, Norikazu Monma, Kazuho Ikeo, Kaoru Mogushi, Yasunari Yamanaka, Hiromichi Matsushita, Takashi Miida, Yoshihide Hayashizaki, Michael Andreeff
Journal: Blood (2015)
PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells.
Authors: Savita Bhalla, Leo I. Gordon, Amareshwar Singh, Sairah Ahmed, Danijela Dokic, Crystal James, Paul T Schumacker, Andrew M Evens
Journal: Blood (2009)
OP0224 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study: Table 1.
Authors: R. Westhovens, R. Alten, D. Pavlova, F.E. Enriquez Sosa, M. Mazur, M. Greenwald, Aa A. Van der, F. Vanhoutte, C. Tasset, P. Harrison
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Filgotinib (GLPG0634) is a novel oral selective JAK1 inhibitor that was evaluated in a 24-week phase 2B study in combination with methotrexate (MTX) in active rheumatoid arthritis (RA) with inadequate response to MTX. The primary endpoint of proportion of patients achieving ACR20 response after 12 weeks of treatment was met. <h3>Objectives</h3> To present the results of the 24-week analysis. <h3>Methods</h3> Patients with active RA on stable dose of MTX were randomized 1:1:1:1:1:1:1 in a double blinded manner to receive either placebo (PBO) or one of three doses of filgotinib (50mg, 100mg or 200mg) as once (qd) or twice daily (bid) regimen for 24 weeks (DARWIN 1 study). At Week 12, patients on placebo and 50mg dose whose tender and swollen joint counts did not improve by 20% (non-responders (NR)) were reassigned to 100mg daily. <h3>Results</h3> 594 randomized and treated patients, mean duration of RA of 7–10 years and mean DAS28(CRP) at baseline 6.0–6.2. At Week 12, statistically significant and dose dependent higher ACR20, ACR50, ACR70, DAS28(CRP) and CDAI responses versus PBO were observed in patients on filgotinib. These responses were maintained or continued to improve through 24 weeks (Table 1). Increase in filgotinib dose from Week 12 lead to improved efficacy in PBO and 50mg NR groups (at Week 24 ACR20 57% and 42% respectively). Serious Adverse Events and Treatment-Emergent Adverse Events (TEAE) were distributed over the groups including PBO: TEAE 51% PBO and 52% filgotinib groups. No opportunistic infections or cancers occurred; one death was reported. Infections occurred in 19% PBO and 25% filgotinib groups. Laboratory parameters remained stable between 12 and 24 weeks. Increase in haemoglobin was noted in patients on filgotinib. <h3>Conclusions</h3> Significant improvement in signs and symptoms of active RA was observed after 12 weeks and sustained or increased up to Week 24 with filgotinib in combination with MTX. The safety profile was overall acceptable. <h3>Disclosure of Interest</h3> R. Westhovens Grant/research support from: Roche, BMS, Janssen, Galapagos NV: investigator DARWIN 1, R. Alten Grant/research support from: Galapagos NV: investigator DARWIN 1, D. Pavlova Grant/research support from: Galapagos NV: investigator DARWIN 1, F. E. Enriquez Sosa Grant/research support from: Galapagos NV: investigator DARWIN 1, M. Mazur Grant/research support from: Galapagos NV: investigator DARWIN 1, M. Greenwald Grant/research support from: Galapagos NV: investigator DARWIN 1, A. Van der Aa Employee of: Galapagos NV, F. Vanhoutte Shareholder of: Galapagos NV, Employee of: Galapagos NV, C. Tasset Employee of: Galapagos NV, P. Harrison Employee of: Galapagos NV
The CD34+ Cell Dose, Even in an "Acceptable" Range, Affects Outcome of Allogeneic Blood Stem Cell Transplantation.
Authors: Seema Singhal, L. Gordon, R. Meagher, A. Evens, M. Tallman, S. Williams, J. Winter, D. Grinblatt, L. Kaminer, J. Mehta
Journal: Blood (2004)
A Multicentric Prospective Phase 2 Study of Intravenous Rituximab and Intrathecal Liposomal Cytarabine in Combination with C5R Protocol Followed by Brain Radiotherapy for Immunocompetent Patients with Primary CNS Lymphoma: A Lymphoma Study Association (LYSA) Trial
Authors: Herve Ghesquieres, Herve Tilly, Anne Sonet, Jehan Dupuis, Alexia Schwartzmann, Emmanuelle Nicolas-Virelizier, Marc Andre, Fabienne Trullemans, Emmanuel Fleck, Sami Boussetta, Franck Morschhauser, Jean-Yves Blay
Journal: Blood (2012)
A Lack of Correlation between EVI1 Expression, MDS Subtype and Karyotype Abnormalities Suggests Multiple Pathways Involved in EVI1 Impact on Hematopoietic Cells in MDS Patients.
Authors: Jaroslav Cermak, Ota Fuchs Ing, Dana Provaznikova, Kyra Michalova, Dana Mikulenkova, Jana Brezinova, Pavel Klener
Journal: Blood (2007)
Relapse-Risk Stratification in Acute Promyelocytic Leukemia Patients by PML-RARa Transcript Quantification.
Authors: Carlos Santamaría, María C. Chillón, Carina Fernández, Patricia Martín-Jiménez, Miguel Alcoceba, María E. Sarasquete, Ana Balanzategui, Ramón García-Sanz, J.F. San Miguel, Marcos González
Journal: Blood (2006)
Abortion Surveillance — United States, 2013
Authors: Tara C. Jatlaoui, Alexander Ewing, Michele G. Mandel, Katharine B. Simmons, Danielle B. Suchdev, Denise J. Jamieson, Karen Pazol
Journal: MMWR Surveillance Summaries (2016)

Problem/Condition: Since 1969, CDC has conducted abortion surveillance to document the number and characteristics of women obtaining legal induced abortions in the United States.
OC-040 National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom
Authors: MN Quraishi, J Segal, B Mullish, V McCune, P Hawkey, A Colville, H Williams, A Hart, TH Iqbal
Journal: Gut (2016)

<h3>Introduction</h3> The National Institute of Health and Care Excellence recommend the use of faecal microbiota transplantation (FMT) for recurrent or refractory <i>Clostridium difficile</i> infection (CDI), as studies have shown it to be a highly effective therapy with a primary cure rate of over 90%.<sup>1</sup> We aimed to conduct a National survey to explore current practice of FMT and the challenges faced by hospitals in setting up this novel treatment strategy. <h3>Methods</h3> UK gastroenterologists, microbiologists and infectious disease physicians were invited to take part in a National survey by completing an online questionnaire over a five month period from October 2015. <h3>Results</h3> A total of 255 responses were obtained, of which 219 were evaluable. These came from 124 microbiologists/infectious disease clinicians and 95 gastroenterologists. The survey covered 130 independent sites: 112 acute NHS Trusts in England, 9 hospitals in Scotland and 9 hospitals in Wales. Only 28% (36/130) had performed FMT for refractory or recurrent CDI, of which 58% (21/36) of sites had experience of performing FMT for over 1 year, but only 19% (7/36) had treated at least 10 patients. 67% (24/36) made FMT on site while 33% (12/36) obtained FMT from elsewhere to administer at their hospital. Apart from one site that used FMT for refractory ulcerative colitis there were no other indications for its use. Of the 94 independent sites that did not perform FMT for refractory or recurrent CDI, 45% (42/94) believed that they were unable to do it due to lack of facilities, 38% (36/94) did not know where to start, however only 5% (5/94) felt reluctant to do it because of its perceived unpleasantness. Of those sites not performing the procedure, 70% (66/94) suggested that they would be keen to have support in setting up an FMT service for CDI locally. Only 29% (27/94) of the sites that did not perform FMT had referred their patients elsewhere; primarily to Glasgow, Birmingham and Exeter. <h3>Conclusion</h3> In the largest National survey done to date exploring the practice of FMT in UK, we have shown that only a quarter of responding sites performed FMT for recurrent or refractory CDI. There are significant challenges faced by hospitals in setting up this service. However, most welcomed support due to unfamiliarity with the perceived logistical hurdles. A central quality controlled and regulated FMT preparation, delivery and support service for the UK may be an efficient model to ensure continued and safe access to this novel treatment strategy for patients in the NHS. <h3>Reference</h3> 1 https://www.nice.org.uk/guidance/ipg485 <h3>Disclosure of Interest</h3> None Declared